Business Wire

Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors

23.12.2025 15:00:00 EET | Business Wire | Press release

Share

Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/

The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service

With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals not just tourist-oriented establishments.

While multilingual services were previously available through web browsers, the official app has been released to provide an enhanced search and reservation experience for the growing number of international visitors, from trip planning to their actual stay in Japan. In the same month, it achieved No. 1 in downloads in the "Japanese Gourmet Search Apps Chosen by International Travelers" ranking(*2).

Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r

About the Tabelog Multilingual Smartphone App

Background

While "Japanese cuisine" is cited as a top highlight of visiting Japan(*5), travelers often express frustrations such as "only finding tourist-oriented restaurants" and challenges like "giving up on phone reservations because Japanese-language communication is required"(*6). As Japan's largest restaurant search and reservation service, Tabelog has developed this smartphone app leveraging the extensive database and expertise cultivated through its web version to address these pain points.

By providing locally-rated restaurant information in multiple languages, Tabelog aims to connect travelers with neighborhood dining establishments, contributing to the alleviation of overtourism and the revitalization of regional economies.

Key Features

  1. [SEARCH] Map-Based Search and Comprehensive Information to Find Restaurants That Match Your Preferences Near Your Current Location
    Utilizing Tabelog's database boasting Japan's largest number of listings, users can intuitively locate restaurants that match their preferences on a map near their current location. With abundant photos and reviews easily accessible on the go, travelers can confidently choose restaurants even in unfamiliar areas.
  2. [RESERVATION] Instant Online Booking Completed on Your Smartphone — No Phone Calls Required
    We've eliminated the barrier of "phone reservations" that pose challenges for travelers. Simply select your date, time, and party size within the app to instantly check availability and make online reservations whether you're on a train or between sightseeing activities. Secure your table smoothly without concerns about language barriers.
  3. [UI] Smartphone-Optimized Interface for Comfortable Navigation in Your Preferred Language
    Fully supports English, Chinese (Traditional), and Korean. The multilingual service previously available on the web version now features the smooth operability unique to mobile apps. Beyond viewing translated information, the intuitive design allows users to deeply understand and choose restaurants without stress, even on smaller screens.

(*1)

Restaurant search and reservation site with the most listed establishments survey (May 2024/internal research). Accessed target sites (Tabelog, Hot Pepper Gourmet, Gurunavi, Retty, Hitosara) and tallied all listed establishments displayed in searches without filtering, by prefecture.

(*2)

November 2025/AppTweak research. Combined downloads from "Food & Drink (Restaurants & Cafes)" and "Travel & Navigation (Trip Planner)" categories on App Store and Google Play in surveyed regions (Taiwan, Hong Kong, South Korea, United States). Compared as "Japanese Gourmet Search Apps."

Source: AppTweak (https://www.apptweak.com)

(*3)

96.73 million users (September 2025)

(*4)

As of December 23, 2025

(*5)

According to the Japan Tourism Agency's "Consumption Trend Survey for Foreigners Visiting Japan (2024)," "eating Japanese food" ranked first in "what they most looked forward to before visiting Japan" and "what they actually did."

(*6)

Refers to "communication with facility staff" and "insufficient multilingual signage" being cited as top difficulties during travel in the Japan Tourism Agency's "Survey on Improving the Accept Environment for Foreign Visitors" and similar studies.

About Kakaku.com, Inc.

Founded in 1997, Kakaku.com has been operating since the early days of Japan's internet era. Currently, the company plans and operates various web services deeply rooted in daily life, including the purchasing support site "Kakaku.com," restaurant search and reservation service "Tabelog," and job search aggregation service "Kyujin Box." Listed on the Tokyo Stock Exchange Prime Market (Securities Code: 2371), the company provides platforms with the largest user bases in Japan across multiple sectors.

Service Overview: https://corporate.kakaku.com/en/service

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251221963753/en/

Contacts

Kakaku.com, Inc.
Public Relations and Investor Relations Office
pr@kakaku.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye